Moderna (MRNA) Misses Q1 EPS by $1.38, Beats on Revenue

Moderna (NASDAQ: MRNA) reported Q1 EPS of ($3.40), $1.38 worse than the analyst estimate of ($2.02). Revenue for the quarter came in at $389 million versus the consensus estimate of $251.76 million.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
• AMD hits $1 trillion market cap for first time amid AI boom
• RBC Capital Upgrades Telix Pharmaceuticals Ltd (TLX:AU) (TLX) to Outperform